InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet and CGuard stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS), a mesh carotid stent designed to improve patient safety through sustained embolic protection which is used for carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, class IIa neuroprotection system for transcarotid access and neuro protection; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.

InspireMD Inc.

Lake Street analyst Frank Takkinen reiterated a Buy rating on InspireMD today and set a price target of $5.00. Takkinen covers the Healthcare secto...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NSPR	$1.95	0.00%	58.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NSPR	$1.95	0%	58.53K
3
4
5
6

NSPR

NSPR

Get InspireMD Inc. Data in Excel

Get InspireMD Inc. Data in Excel